Market revenue in 2022 | USD 1,108.7 million |
Market revenue in 2030 | USD 1,967.7 million |
Growth rate | 7.4% (CAGR from 2022 to 2030) |
Largest segment | Reagents & consumables |
Fastest growing segment | Reagents & Consumables |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Analyzers, Reagents & Consumables |
Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.26% in 2022. Horizon Databook has segmented the Asia Pacific thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is expected to witness significant growth due to the local presence of leading thrombosis and hemostasis biomarker companies and an increase in R&D investment. There has been an increase in R&D investments in China, India, and Japan, which has accelerated the development of thrombosis and hemostasis biomarkers.
In addition, there has been an increase in the population and disposable income in developing countries such as India, Japan, and China. Growing geriatric population susceptible to diseases and rising prevalence of target diseases, such as cardiovascular diseases and blood clotting disorders, are anticipated to propel the Asia Pacific market over the coming years.
For instance, according to research published in ScienceDirect, there were 18.6 million CVD deaths globally in 2019, of which, 58% occurred in Asia Pacific. Diverse reimbursement policies in Asia Pacific for biomarker testing are influencing the market in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account